GH Research (NASDAQ:GHRS) Stock Rating Upgraded by Wall Street Zen

Posted by Geri Gentry on Aug 10th, 2026

GH Research (NASDAQ:GHRS – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research analysts have also commented on GHRS. HC Wainwright decreased their price target on shares of GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Wells Fargo & Company started coverage on shares of GH Research in a research note on Monday, July 27th. They set an “overweight” rating and a $44.00 price objective on the stock. Guggenheim raised their target price on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research note on Friday, July 17th. Finally, Cantor Fitzgerald upped their target price on GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Friday. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, GH Research has a consensus rating of “Moderate Buy” and an average price target of $42.78.

View Our Latest Analysis on GH Research

GH Research Price Performance

GH Research stock opened at $30.27 on Friday. The company has a market cap of $2.08 billion, a PE ratio of -30.27 and a beta of 1.29. The company has a fifty day moving average price of $25.70 and a two-hundred day moving average price of $20.19. GH Research has a 12 month low of $11.32 and a 12 month high of $31.44.

GH Research (NASDAQ:GHRS – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. Equities research analysts anticipate that GH Research will post -1.42 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of GH Research during the second quarter worth about $79,000. BNP Paribas Financial Markets lifted its position in GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares during the last quarter. Osaic Holdings Inc. lifted its position in GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the last quarter. UBS Group AG grew its position in GH Research by 11.5% in the 3rd quarter. UBS Group AG now owns 511,464 shares of the company’s stock worth $7,314,000 after purchasing an additional 52,882 shares during the last quarter. Finally, Lynx1 Capital Management LP increased its stake in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after purchasing an additional 1,854,238 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

(Get Free Report)

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.